Białko KRAS – struktura, aktywność i rola w terapiach przeciwnowotworowych

• Autorzy: Łopatko Dagmara , Młynarz Piotr , Jewgiński Michał

Identyfikatory

DOI

10.15199/5.2024.1.4

Warianty tytułu

EN

KRAS protein – structure, activity and role in anticancer therapies

• Języki publikacji: PL

Abstrakty

PL

Białko KRAS w formie natywnej występuje w organizmie w formie aktywnej, wiążącej GTP lub nieaktywnej, wiążącej GDP. Formy te podlegają cyklicznym, ściśle regulowanym przemianom, dzięki czemu odgrywa ono kluczową rolę w regulacji szlaków sygnalizacyjnych związanych z proliferacją i przeżywalnością komórek. Jednakże białko to jest jednym z najczęściej mutujących onkogenów rodziny białek RAS, które prowadzą do jego niekontrolowanej nadaktywności, a poszczególne jego mutacje powiązane są z licznymi formami nowotworów, które jeszcze do niedawna traktowane były jako „nieuleczalne”.

EN

The KRAS protein in its native form occurs in the body in anactive form - binding GTP and inactive-binding GDP. These forms are subject to cyclical, tightly regulated transformations, which play a crucial role in regulating signaling pathways related to cell proliferation and survival. However, this protein is one of the most frequently mutating oncogenes of the RAS protein family, which leads to its uncontrolled hyperactivity, and its mutations are associated with numerous forms of cancer that until recently were considered as “incurable”.

Słowa kluczowe

PL

mutacja; nowotwór; inhibitor; przełącznik I i II

EN

mutation; cancer; inhibitor; switch I and II

• Wydawca: Stowarzyszenie Inżynierów i Techników Przemysłu Chemicznego, ZW CHEMPRESS-SITPChem ; Politechnika Wrocławska
• Czasopismo: Chemik
• Rocznik: 2024
• Tom: Nr 1
• Strony: 56--62
• Opis fizyczny: Bibliogr. 39 poz., rys.

Twórcy

autor

Łopatko Dagmara

• Katedra Chemii Bioorganicznej, Wydział Chemiczny, Politechnika Wrocławska, Wybrzeże Wyspiańskiego 27, 50-370 Wrocław, Polska

autor

Młynarz Piotr

• Politechnika Wrocławska, Wydział Chemiczny

autor

Jewgiński Michał

• Katedra Chemii Bioorganicznej, Wydział Chemiczny, Politechnika Wrocławska, Wybrzeże Wyspiańskiego 27, 50-370 Wrocław, Polska

Bibliografia

• [1] C. V Dang, E. P. Reddy, K. M. Shokat, and L. Soucek, “Drugging the ‘undruggable’ cancer targets,” Nat. Rev. Cancer, vol. 17, no. 8, pp. 502–508, 2017, doi: 10.1038/nrc.2017.36.
• [2] H. Sung et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA. Cancer J. Clin., vol. 71, no. 3, pp. 209–249, May 2021, doi: https://doi.org/10.3322/caac.21660
• [3] A. D. Cox and C. J. Der, “Ras history,” Small GTPases, vol. 1, no. 1, pp. 2–27, Jul. 2010, doi: 10.4161/sgtp.1.1.12178.
• [4] J. Timar and K. Kashofer, “Molecular epidemiology and diagnostics of KRAS mutations in human cancer,” Cancer Metastasis Rev., vol. 39, no. 4, pp. 1029–1038, 2020, doi: 10.1007/s10555-020-09915-5.
• [5] K. Parikh et al., “Drugging KRAS: current perspectives and state-of-art review,” J. Hematol. Oncol., vol. 15, no. 1, p. 152, 2022, doi: 10.1186/s13045-022-01375-4.
• [6] J. C. Hunter, A. Manandhar, M. A. Carrasco, D. Gurbani, S. Gondi, and K. D. Westover, “Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations,” Mol. Cancer Res., vol. 13, no. 9, pp. 1325–1335, Sep. 2015, doi: 10.1158/1541-7786.MCR-15-0203.
• [7] K. Nyíri, G. Koppány, and B. G. Vértessy, “Structure-based inhibitor design of mutant RAS proteins—a paradigm shift,” Cancer Metastasis Rev., vol. 39, no. 4, pp. 1091–1105, 2020, doi: 10.1007/s10555-020-09914-6.
• [8] J. M. Ostrem, U. Peters, M. L. Sos, J. A. Wells, and K. M. Shokat, “K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions,” Nature, vol. 503, no. 7477, pp. 548–551, 2013, doi: 10.1038/nature12796.
• [9] K. S. De, “Sotorasib: First Approved KRAS Mutation Inhibitor for the Treatment of Non-small Cell Lung Cancer,” Current Medicinal Chemistry, vol. 30, no. 9, pp. 1000–1002, 2023, doi: http://dx.doi.org/10.2174/0929867329666220907161505.
• [10] G. A. Hobbs, C. J. Der, and K. L. Rossman, “RAS isoforms and mutations in cancer at a glance,” J. Cell Sci., vol. 129, no. 7, pp. 1287–1292, Apr. 2016, doi: 10.1242/jcs.182873.
• [11] A. E. Karnoub and R. A. Weinberg, “Ras oncogenes: split personalities,” Nat. Rev. Mol. Cell Biol., vol. 9, no. 7, pp. 517–531, 2008, doi: 10.1038/nrm2438.
• [12] A. García-España and M. R. Philips, “Origin and Evolution of RAS Membrane Targeting,” Oncogene, vol. 42, no. 21, pp. 1741–1750, 2023, doi: 10.1038/s41388-023-02672-z.
• [13] J. Kochen Rossi, C. Nuevo-Tapioles, and M. R. Philips, “Differential functions of the KRAS splice variants,” Biochem. Soc. Trans., vol. 51, no. 3, pp. 1191–1199, May 2023, doi: 10.1042/BST20221347.
• [14] M. Janakiraman et al., “Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer,” Cancer Res., vol. 70, no. 14, pp. 5901–5911, Jul. 2010, doi: 10.1158/0008-5472.CAN-10-0192.
• [15] J. M. L. Ostrem and K. M. Shokat, “Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design,” Nat. Rev. Drug Discov., vol. 15, no. 11, pp. 771–785, 2016, doi: 10.1038/nrd.2016.139.
• [16] Y. Li, L. Han, and Z. Zhang, “Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation,” Comput. Struct. Biotechnol. J., vol. 20, pp. 1056–1067, Jan. 2022, doi: 10.1016/j.csbj.2022.02.018.
• [17] S. Cao, S. Chung, S. Kim, Z. Li, D. Manor, and M. Buck, “K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function,” J. Biol. Chem., vol. 294, no. 17, pp. 7068–7084, Apr. 2019, doi: 10.1074/jbc.RA118.004021.
• [18] M. Schmick et al., “KRas Localizes to the Plasma Membrane by Spatial Cycles of Solubilization, Trapping and Vesicular Transport,” Cell, vol. 157, no. 2, pp. 459–471, Apr. 2014, doi: 10.1016/j.cell.2014.02.051.
• [19] S. L. Campbell and M. R. Philips, “Post-translational modification of RAS proteins,” Curr. Opin. Struct. Biol., vol. 71, pp. 180–192, 2021, doi: https://doi.org/10.1016/j.sbi.2021.06.015
• [20] X. Nan et al., “Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway,” Proc. Natl. Acad. Sci., vol. 112, no. 26, pp. 7996–8001, Jun. 2015, doi: 10.1073/pnas.1509123112.
• [21] J. Cherfils and M. Zeghouf, “Regulation of Small GTPases by GEFs, GAPs, and GDIs,” Physiol. Rev., vol. 93, no. 1, pp. 269–309, Jan. 2013, doi: 10.1152/physrev.00003.2012.
• [22] Z. Zhao, N. Bohidar, and P. E. Bourne, “Analysis of KRAS–Ligand Interaction Modes and Flexibilities Reveals the Binding Characteristics,” J. Chem. Inf. Model., vol. 63, no. 4, pp. 1362–1370, Feb. 2023, doi: 10.1021/acs.jcim.3c00097.
• [23] M. Roman, E. Hwang, and E. A. Sweet-Cordero, “Synthetic Vulnerabilities in the KRAS Pathway,” Cancers, vol. 14, no. 12, 2022, doi: 10.3390/cancers14122837.
• [24] M. Nagasaka, Y. Li, A. Sukari, S.-H. I. Ou, M. N. Al-Hallak, and A. S. Azmi, “KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?,” Cancer Treat. Rev., vol. 84, Mar. 2020, doi: 10.1016/j.ctrv.2020.101974.
• [25] M. V Milburn et al., “Molecular Switch for Signal Transduction: Structural Differences Between Active and Inactive Forms of Protooncogenic ras Proteins,” Science (80-. ), vol. 247, no. 4945, pp. 939–945, Feb. 1990, doi: 10.1126/science.2406906.
• [26] D. Filchtinski, O. Sharabi, A. Rüppel, I. R. Vetter, C. Herrmann, and J. M. Shifman, “What Makes Ras an Efficient Molecular Switch: A Computational, Biophysical, and Structural Study of Ras-GDP Interactions with Mutants of Raf,” J. Mol. Biol., vol. 399, no. 3, pp. 422–435, 2010, doi: https://doi.org/10.1016/j.jmb.2010.03.046.
• [27] T. Takács, G. Kudlik, A. Kurilla, B. Szeder, L. Buday, and V. Vas, “The effects of mutant Ras proteins on the cell signalome,” Cancer Metastasis Rev., vol. 39, no. 4, pp. 1051–1065, 2020, doi: 10.1007/s10555-020-09912-8.
• [28] A. K. Murugan, M. Grieco, and N. Tsuchida, “RAS mutations in human cancers: Roles in precision medicine,” Semin. Cancer Biol., vol. 59, pp. 23–35, 2019, doi: https://doi.org/10.1016/j.semcancer.2019.06.007
• [29] L. Huang, Z. Guo, F. Wang, and L. Fu, “KRAS mutation: from undruggable to druggable in cancer,” Signal Transduct. Target. Ther., vol. 6, no. 1, p. 386, 2021, doi: 10.1038/s41392-021-00780-4.
• [30] D. Rabara et al., “KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis,” Proc. Natl. Acad. Sci., vol. 116, no. 44, pp. 22122–22131, Oct. 2019, doi: 10.1073/pnas.1908353116.
• [31] S. Dogan et al., “Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers,” Clin. Cancer Res., vol. 18, no. 22, pp. 6169–6177, Nov. 2012, doi: 10.1158/1078-0432.CCR-11-3265.
• [32] F. Liu, X. Yang, M. Geng, and M. Huang, “Targeting ERK, an Achilles’ Heel of the MAPK pathway, in cancer therapy,” Acta Pharm. Sin. B, vol. 8, no. 4, pp. 552–562, Jul. 2018, doi: 10.1016/j.apsb.2018.01.008.
• [33] Y. Peng, Y. Wang, C. Zhou, W. Mei, and C. Zeng, “PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?,” Front. Oncol., vol. 12, 2022, doi: 10.3389/fonc.2022.819128.
• [34] J. Canon et al., “The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity,” Nature, vol. 575, no. 7781, pp. 217–223, 2019, doi: 10.1038/s41586-019-1694-1.
• [35] T. Pantsar, “KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations,” Sci. Rep., vol. 10, no. 1, p. 11992, 2020, doi: 10.1038/s41598-020-68950-y.
• [36] T. Pantsar, “The current understanding of KRAS protein structure and dynamics,” Comput. Struct. Biotechnol. J., vol. 18, pp. 189–198, Jan. 2020, doi: 10.1016/j.csbj.2019.12.004.
• [37] V. Dunnett-Kane, P. Nicola, F. Blackhall, and C. Lindsay, “Mechanisms of Resistance to KRASG12C Inhibitors,” Cancers, vol. 13, no. 1, 2021, doi: 10.3390/cancers13010151.
• [38] A. R. Issahaku et al., “Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy,” Sci. Rep., vol. 12, no. 1, p. 17796, 2022, doi: 10.1038/s41598-022-22668-1.
• [39] D. Tang and R. Kang, “Glimmers of hope for targeting oncogenic KRASG12D,” Cancer Gene Ther., vol. 30, no. 3, pp. 391–393, 2023, doi: 10.1038/s41417-022-00561-3.